Baird analyst Brian Skorney raised his price target on Neurocrine to $122 from $100 following the elagolix approval for endometriosis. The price target reflects the greater certainty of sales and he believes the drug will be a blockbuster across multiple women’s health indications. Skorney reiterated his Outperform rating on Neurocrine shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.